Funded projects focus on alleviating complications of PD treatment and addressing patients' unmet needs.

Statins may slow the progression of Parkinson's disease by preventing the cascade of inflammatory damage to neurons that eventually leads to motor dysfunction, according to a mouse model study.

Share a day of education and advocacy with Parkinson’s advocates in your community and across the country.

On Saturday, November 21, MJFF will Webcast the third of three 2009 Research Roundtables live to allow you to hear from our expert panel and submit your own questions on PD and the state of research toward a cure -- from the comfort of your own personal computer. Register now!

On November 21, 2009, The Michael J. Fox Foundation will host its annual gala, “A Funny Thing Happened on the Way to Cure Parkinson’s.”

The Michael J. Fox Foundation announced $5.2 million in support for two studies defining the clinical presentation of PD in two populations in which LRRK2 gene mutations are associated with a significantly increased risk of PD.

Team Fox member Chris Grannan will be running in the footsteps of his late father when he tackles the ING NYC Marthon to support MJFF.

Alyssa Johnson, a Team Fox member who ran the 2007 NYC marathon for MJFF, is featured in the New York Times, as part of the "Running Voices" series.

MJFF and NYAS hosted the Third Annual PD Therapeutics Conference, the only major scientific symposium exclusively focused on speeding therapeutic development for Parkinson’s disease.

The researchers have identified two drug-like molecules that, when given systematically in a pre-clinical model of Parkinson’s disease, reduce PD symptoms by acting on a specific glutamate receptor in the brain called the metabotropic glutamate receptor, or mGluR4. Also available: A News in Context Q&A with Dr. Conn on the significance of the finding, and next steps.

MJFF is now a registered, tax-exempt charity in Canada. The official launch was celebrated with a day of events in Toronto.

Edmonton-born actor and philanthropist Michael J. Fox was in Toronto on Thursday to announce his Parkinson's research foundation is now a tax-exempt charity in Canada.

The funding, aimed at to successfully translating neurotrophic factor advances from pre-clinical and early-phase clinical work into a practical, patient-relevant treatment for Parkinson’s disease, will be awarded under a new directed LEAPS (Linked Efforts to Accelerate Parkinson’s Solutions) initiative.

The Canadian actor's foundation is taking an aggressive, entrepreneurial approach to science.

Funding is open to academic and industry researchers through the Foundation’s 2010 Pipeline Programs.

The Michael J. Fox Foundation for Parkinson’s Research is now a registered, tax-exempt charity in Canada. MJFF will be formally marking its official launch with a day-long celebration in Toronto on September 24, 2009 in association with the McEwen Centre for Regenerative Medicine and Toronto’s Western Hospital, part of the University Health Network.

The National MS and Parkinson's Disease Registries Act will establish a national system to collect information that is vital to Parkinson's research. Take action by contacting your Members of Congress and asking them to cosponsor this important legislation.

If you're passing through New York City during the month of August, be sure to check out MJFF's window display in the heart of Rockefeller Center.

Focusing on health care delivery is not enough, writes MJFF CEO Katie Hood on her Huffington Post blog. Long-term solutions to the United States’ health care mess must address the roots of the problem: our inefficient system for developing new treatments in the first place.

Funded investigations aim to push forward novel neuroprotective and improved symptomatic therapies as well as new strategies for addressing complications of treatment.

The Michael J. Fox Foundation for Parkinson’s Research announced approximately $2.1 million in total funding to 10 research teams working to validate therapeutic targets for Parkinson’s disease.

The Michael J. Fox Foundation has signed on to fund the long-term, open-label analysis of data from Ceregene, Inc.’s Phase 2 trial of CERE-120, a gene therapy approach to deliver trophic factor neurturin to the brains of Parkinson’s patients. The funding will allow Ceregene to collect and analyze data from trial enrollees for another 48 months.

On Tuesday, June 23, The Michael J. Fox Foundation Webcast the second of three 2009 Virtual Research Roundtables. Log on to watch the event video.

As of mid-2009, The Michael J. Fox Foundation for Parkinson’s Research has already funded over $1 million in high-risk, high-reward approaches to Parkinson’s therapeutic development through its groundbreaking Rapid Response Innovation Awards.

The Michael J. Fox Foundation announced the launch of a new Web-based community to increase collaboration and resource-sharing in the global PD scientific community.

Join representatives of MJFF in Philadelphia on Friday evening, June 26, for an MJFF Research Review followed by a reception with open beer and wine bar and auction.

Join MJFF CEO Katie Hood, Associate Director of Research Programs Mark Frasier, PhD, and three leading PD researchers for a presentation on current Parkinson's research and expert Q&A in Boston on Tuesday evening, June 23.

The Michael J. Fox Foundation's fourth round of biomarker funding aims to continue stimulating discovery of new disease and drug biomarkers.

Reporting for WowOwow (Women on the Web), MJFF Board member Holly S. Andersen, MD, talked one-on-one with Michael J. Fox about his recent book, Always Looking Up: The Adventures of an Incurable Optimist, upcoming projects and his enduring power as he struggles with Parkinson’s disease.

MJFF provides analysis of recent papers on genes and disease, and discusses implications for ongoing research into the genetics of Parkinson’s disease.

Come and join thousands in Manhattan's beautiful Central Park on Saturday, April 25, 2009, for an event-filled day at the 15th Parkinson's Unity Walk. 

Registration is now open for the 2009 PD Therapeutics Conference,organized by The Michael J. Fox Foundation and the New York Academy of Sciences and taking place in New York City on September 30, 2009.

April is Parkinson's Awareness Month and The Michael J. Fox Foundation has teamed up with Tonic.com to make sure that the powerful, inspirational stories of people living with Parkinson’s are told and that readers can learn the facts about PD.

The Michael J. Fox Foundation for Parkinson’s Research will award up to $6.5 million in total funding under three Critical Challenges research programs designed to accelerate solutions to some of the most difficult hurdles standing in the way of breakthrough therapeutics for PD.

The Michael J. Fox Foundation announced that it has awarded approximately $2.1 million total to seven research teams working to improve drug delivery for Parkinson’s disease.

Read an MJFF News in Context on recent news from researchers at Duke University that by electrically stimulating the spinal cords of rodents, they have reversed some of the worst symptoms of Parkinson’s disease.

The Michael J. Fox Foundation will hold a Research Roundtable in Los Angeles, California on May 29. Please check our Web site in the coming weeks for more details.

The first FOX Sports Supports campaign was launched in 2008 to increase awareness and raise funds for worthy health-related charities. After a highly successful inaugural year working, the program returns for a second campaign with four new inspiring organizations, including The Michael J. Fox Foundation.

The Michael J. Fox Foundation for Parkinson’s Research seeks applications from industry researchers under its $5-million Therapeutics Development Initiative (TDI). The Foundation also announced that, going forward, TDI will be launched bi-annually.

MJFF CEO Katie Hood blogs about MJFF's role in the 23andMe Parkinson's Disease Community announced this week -- and why MJFF is excited about the opportunities the Internet could present for changing the way biomedical research gets done.

Limited-time special offer will make 23andMe personal genetics service available to people with PD for $25 instead of standard $399

MJFF CEO Katie Hood blogs about being present in the East Room as President Obama signed the historic executive order lifting former restrictions on federal funding for embryonic stem cell research.

Because of needed maintenance to the external server that processes online applications to The Michael J. Fox Foundation, our online grant application system will be unavailable from  10 a.m. Saturday, March 28, to 4 a.m. Sunday, March 29 (all times U.S. ET).

Read statements from Michael J. Fox and Katie Hood on President Obama's overturn of the ban on federal funding for embryonic stem cell research -- as well as a News in Context discussing the implications for Parkinson's research.

For Team Fox news, discussions, event information, videos and more, visit the Team Fox blog.

At her Huffington Post blog, MJFF CEO Katie Hood urges President Obama to fulfill his campaign commitment to overturn Bush-era policy on stem cell research.

The Michael J. Fox Foundation for Parkinson’s Research awarded approximately $1.9 million total to six teams working to develop neuroimaging technologies that would allow scientists to non-invasively visualize the clumping of the alpha-synuclein protein in the living human brain.

On Monday, February 9, The Michael J. Fox Foundation Webcast the first of three Virtual Research Roundtables for 2009. Video of the event is now available -- hear from our expert panel on Parkinson’s disease and the state of research toward a cure.

The Michael J. Fox Foundation spoke to Raymond T. Bartus, PhD, executive vice president and chief scientific officer of Ceregene, Inc., about the news that Ceregene’s Phase 2 clinical trial of CERE-120 (the company’s gene therapy approach to deliver trophic factor neurturin to the brains of Parkinson’s patients) failed to show a difference between treatment and placebo.

The Michael J. Fox Foundation for Parkinson’s Research has awarded $2.5 million total for seven Parkinson’s drug development projects. The funding was awarded under a special, one-time academic funding track of the Foundation’s industry-focused Therapeutics Development Initiative.

On Monday, February 9, The Michael J. Fox Foundation will Webcast the first of three Virtual Research Roundtables for 2009. You are invited to log on from the comfort of your home computer to hear from our expert panel and submit your own questions on Parkinson’s disease and the state of research toward a cure. Register now!

The Michael J. Fox Foundation for Parkinson’s Research cordially invites you to attend a Research Roundtable presentation: Our Funding Philosophy and Research Portfolio Highlights.

For decades, we all have counted on the private sector to drive progress toward new drugs and treatments for disease. In an era of change, we may need to reconsider a more deliberate role for the public sector in driving discovery into development, and potentially through the first stages of what has been traditionally viewed as 'commercial' development.

The Michael J. Fox Foundation for Parkinson’s Research awarded about $2.9 million total for two clinical studies that will test drugs already approved in other disease indications for potential efficacy against Parkinson’s disease.

The Michael J. Fox Foundation awarded a total of $2.7 million to four industry research teams for pre-clinical research on potential new treatments for Parkinson’s disease.

The Michael J. Fox Foundation invites you to attend a Research Roundtable presentation titled "The MJFF Strategic Research Overview: A novel funding philosophy and Parkinson’s research highlights"